Those late-night pizza runs and impromptu dance parties seemed totally worth the next-day zombie mode. Maybe you were ...

After the terrible earthquake of 1956, its residents cast a black stone behind them, selling their properties—even for a tin ...

Invivyd (IVVD) announced positive data from its ongoing Phase 1/2 clinical trial of VYD2311, Invivyd’s novel monoclonal antibody candidate designed to be a superior alternative to COVID-19 ...

Pyxis Oncology announces Phase 1/2 trials for PYX-201, combining it with KEYTRUDA® to treat advanced solid tumors. Pyxis Oncology, Inc. has announced the initiation of two significant clinical ...

Denali Therapeutics (DNLI) announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome in the 24-week treatment period and additional long-term follow-up of its ...

Beam Therapeutics is set to present positive and significant data from the BEACON Phase 1/2 clinical trial of BEAM-101 at a major conference, enhancing visibility and credibility within the ...

Mumbai: The Brihanmumbai Municipal Corporation (BMC) presented its budget for the financial year 2025–2026 on Tuesday. BMC presented an unprecedented budget of Rs 74,427 crore for the financial ...

We're nearing the end of Phase 5 of the MCU which marks the midway point of The Multiverse Saga, following the releases of Agatha All Along and Deadpool & Wolverine in 2024. This year sees the ...

Ocugen, Inc. announced the positive 2-year safety and efficacy update for the Phase 1/2 OCU400 clinical trial for the treatment of early to advanced retinitis pigmentosa (RP) in pediatric and adult ...

The FDA has approved the investigational new drug application of 225Ac-SSO110, allowing for the start of a phase 1/2 trial in patients with extensive-stage small cell lung cancer and Merkel cell ...

The upcoming Phase 1/2 clinical trial, dubbed RESET-MS, will enroll adults, ages 18-60, who have either relapsing or progressive forms of MS. To be eligible, patients with relapsing MS must have ...

Carnage #1 this week, where Eddie Brock forms his most dangerous symbiote bond yet. Will he control the bloodlust, or will it control him?